Business Wire
05 Jan 2026, 12:30 UTC · 36w ago
Verdict
Headline leans bullish. We score ARWR +0.80 across one claim.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.80strongly bullish
What the story claims
1 claim · scored −1 bearish … +1 bullish
Health Canada has issued a Notice of Compliance authorizing REDEMPLO (plozasiran) for the treatment of familial chylomicronemia syndrome (FCS).
More positive than 91% of claims this week
Which stocks this story touches
Continue reading
5 related stories
More positive than 86% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 86% of ticker scores this week
The company received regulatory authorization from Health Canada for its drug REDEMPLO.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
The Motley Fool
2d ago
−1.9%
Price is moving against the score
$66.48 vs $67.79 close before publication (Jan 2) · not market-adjusted
ARWR chart →
